Clearside picks up $7.9M for microneedle blindness treatment; Ampio embarks on clinical trials for oral diabetic treatment;

@MichaelGFierce: Sanofi's Genzyme hits target with muscular dystrophy RNA drug in mice. Article | Follow @MichaelGFierce

> Clearside Biomedical has raised $7.9 million to finance a microneedle to deliver drugs to the back of the eye for the treatment of retinal blindness, and the startup could raise as much as $8.5 million more before beginning clinical testing in the first quarter of this year, if all goes as planned. Story

> Ampio Pharmaceuticals ($AMPE) began a clinical trial of Optina, its oral version of a drug to treat diabetic macular edema--previous treatments all required an injection directly into the eye. Release

> Intersect ENT received $30 million in Series D funding for its quarter-sized implants to treat chronic sinusitis. The device releases a steroid drug to keep the sinus open and attracted attention from Medtronic ($MDT). Story

> Cumberland Pharmaceuticals and Sandor Medicaids signed a commercialization agreement for an injectable ibuprofen drug in India, marking the first time in the country that the drug is available in such a form. Release

> Results from a Phase III study showed that once-daily, inhaled tiotropium from Boehringer Ingelheim improved lung function in asthma patients who have allergies that affect their reactions to other treatments. Release

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.